Comparison · NCT03732677-deaths
Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Durvalumab + Gemcitabine + Cisplatin vs Gemcitabine + Cisplatin: deaths from any cause. Trial comparisons, record NCT03732677-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03732677-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0507 | 0.035 | 0.0727 | wilson | |
| Risk in group 2 | 0.0551 | 0.0387 | 0.0781 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00448 | -0.0322 | 0.023 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.919 | 0.552 | 1.53 | log | |
| Odds ratio, group 1 over group 2 | 0.914 | 0.534 | 1.57 | log | |
| Number needed to treat, for one fewer death from any cause on Durvalumab + Gemcitabine + Cisplatin than on Gemcitabine + Cisplatin | 223 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Durvalumab + Gemcitabine + Cisplatin | Treatments and dosing regimens: Durvalumab 1500 mg IV q3w (neoadjuvant) 1500 mg IV q4w (adjuvant post-radical cystectomy) Day 1 and Day 8 (gemcitabine 1000 mg/m2 IV) of each 21-day cycle (neoadjuvant) Day 1 and Day 8 (cisplatin 35mg/m2 IV) or Day 1 (cisplatin 70 mg/m2 IV) each 21-day cycle (neoadjuvant) Dosing will be adjusted based on renal function | 27 | 533 | EG000 |
| Group 2 | Gemcitabine + Cisplatin | Treatments and dosing regimens: Day 1 and Day 8 (gemcitabine1000 mg/m2 IV) of each 21-day cycle (neoadjuvant) Day 1 and Day 8 (cisplatin 35mg/m2 IV) or Day 1 (cisplatin 70 mg/m2 IV) each 21-day cycle (neoadjuvant) Dosing will be adjusted based on renal function | 29 | 526 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
Includes AEs between date of first dose and the earliest of: maximum date of (last dose or surgery) + 90days, date of first dose of subsequent anti-cancer therapy. Total follow up about 2 years. The frequency assessment was: Neoadjuvant, every 3 weeks, Post Surgery, every week, Adjuvant and Follow Up: every 4 weeks. All-cause mortality (death due to any cause): from randomization up to EFS IA2 DCO (April 29, 2024). Maximum timeframe of approximately 5.4 years.
Source ClinicalTrials.gov
Trial
- Title
- Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
- NCT number
- NCT03732677
- Phases
- PHASE3
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- Durvalumab, Cisplatin, Gemcitabine
- Lead sponsor
- AstraZeneca
- Results first posted
- 2025-07-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03732677?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03732677-deaths